- Home
- FBIO vs DYAI Comparison
FBIO vs DYAI Comparison
Compare FBIO & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- DYAI
- Stock Information
- Founded
- FBIO 2006
- DYAI 1979
- Country
- FBIO United States
- DYAI United States
- Employees
- FBIO N/A
- DYAI N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBIO Health Care
- DYAI Health Care
- Exchange
- FBIO Nasdaq
- DYAI Nasdaq
- Market Cap
- FBIO 39.4M
- DYAI 31.5M
- IPO Year
- FBIO N/A
- DYAI 2004
- Fundamental
- Price
- FBIO $1.43
- DYAI $1.13
- Analyst Decision
- FBIO Strong Buy
- DYAI Strong Buy
- Analyst Count
- FBIO 4
- DYAI 1
- Target Price
- FBIO $16.33
- DYAI $6.00
- AVG Volume (30 Days)
- FBIO 605.0K
- DYAI 18.7K
- Earning Date
- FBIO 11-14-2024
- DYAI 11-12-2024
- Dividend Yield
- FBIO N/A
- DYAI N/A
- EPS Growth
- FBIO N/A
- DYAI N/A
- EPS
- FBIO N/A
- DYAI N/A
- Revenue
- FBIO $81,501,000.00
- DYAI $3,364,548.00
- Revenue This Year
- FBIO N/A
- DYAI $2.04
- Revenue Next Year
- FBIO $81.63
- DYAI $110.34
- P/E Ratio
- FBIO N/A
- DYAI N/A
- Revenue Growth
- FBIO 31.51
- DYAI 13.82
- 52 Week Low
- FBIO $1.36
- DYAI $0.93
- 52 Week High
- FBIO $4.43
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- FBIO 31.19
- DYAI 52.65
- Support Level
- FBIO $1.66
- DYAI $1.02
- Resistance Level
- FBIO $1.79
- DYAI $1.23
- Average True Range (ATR)
- FBIO 0.13
- DYAI 0.09
- MACD
- FBIO -0.04
- DYAI 0.01
- Stochastic Oscillator
- FBIO 2.90
- DYAI 52.33
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.